Janssen Pharmaceuticals initiated patient dosing in a phase 2b study of different regimens for the treatment of chronic hepatitis B including combinations of JNJ-3989, JNJ-6379 and nucleos(t)ide analog therapy, according to a press release from study collaborator, Arrowhead Pharmaceuticals.
“Patients with chronic hepatitis B infection are in need of new medicines that improve functional cure rates with finite treatment regimens,” Christopher Anzalone, PhD, president and chief executive officer at Arrowhead, said in the release. “We are thrilled that JNJ-3989, formerly ARO-HBV, is one of the agents being investigated in Janssen’s REEF-1 triple combination phase 2b study.”
JNJ-3989 is a liver-targeted antiviral therapeutic designed to treat chronic HBV infection via the ribonucleic acid interference mechanism. JNJ-6379 is an orally administered capsid assembly modulator.
The multicenter, randomized control phase 2b study will include up to 450 patients with chronic HBV who will receive a combination regimen or placebo for up to 48 weeks.
Reference : www.arrowheadpharma.com